Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amylyx Pharmaceuticals excels in Q4 with RELYVRIO launch success

Amylyx Pharmaceuticals demonstrated strong financial performance in Q4 2022, driven by the successful commercial launch of RELYVRIO for ALS treatment.
The company's focus on key priorities for the U.S. launch and commitment to serving ALS patients position it well for future growth and impact.
While facing challenges in meeting analyst expectations and study success criteria, Amylyx Pharmaceuticals remains optimistic about the opportunities ahead in advancing ALS treatment.

Amylyx Pharmaceuticals achieves profitability in Q1, plans global PSP study

Amylyx Pharmaceuticals delivered strong financial performance in Q1, driven by the success of RELYVRIO and plans for AMX0035 in PSP. While facing challenges in profitability expectations and pipeline expansion, the company is well-positioned to capitalize on opportunities for growth and impact.

Amylyx Pharmaceuticals reports robust Q2 performance and strategic growth focus

Amylyx Pharmaceuticals' Q2 2023 Earnings Call highlighted strong financials, patient-centric initiatives, and advancements in R&D programs for neurodegenerative diseases.
Analysts' inquiries underscored the need for clarity on compliance rates, expansion strategies, and study design considerations to address potential challenges.
The company's emphasis on trial design strength, patient support, and market positioning opportunities signals a strategic focus on growth and innovation.

Amylyx Pharmaceuticals reports strong Q3 earnings, eyes growth opportunities

Amylyx Pharmaceuticals had a strong Q3 performance with significant net product revenues and a focus on expanding patient reach. While facing challenges in discontinuations and revenue impact, the company is optimistic about growth opportunities through education and trial results.

Amylyx Pharmaceuticals reports robust earnings, poised for market expansion

Amylyx Pharmaceuticals had a successful year financially, with strong revenue growth and a solid financial position.
The company's focus on expanding market reach, developing innovative biomarkers, and enhancing disease diagnosis underscores their commitment to advancing ALS treatment.
While facing uncertainties with upcoming trial data and regulatory challenges, Amylyx remains optimistic about growth opportunities and R&D advancements.

Amylyx Pharmaceuticals adapts strategy post-PHOENIX trial, eyes regulatory milestones

Amylyx Pharmaceuticals navigated a challenging quarter with a focus on pipeline diversification and strategic planning for multiple neurodegenerative diseases. Despite setbacks in the PHOENIX trial, the company remains resilient and proactive in addressing challenges while seizing opportunities for growth and regulatory progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France.

Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. announced the acceptance of several abstracts for presentation at the 2023 Northeast ALS Consortium Annual Meeting.

RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting

Adaptive Biotechnologies

Iovance Biotherapeutics

Investing in biotech stocks is challenging even when you're investing in established companies with commercially available drugs and expansive pipelines. And investing in up-and-coming biotech stocks is only for the most risk-tolerant investors.

3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations & Communications Justin Klee - Co-Chief Executive Officer Margaret Olinger - Chief Commercial Officer Jim Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Geoff Meacham - Bank of America Michael DiFiore - Evercore Marc Goodman - Leerink Partners Graig Suvannavejh - Mizuho Ananda Ghosh - H.C. Wainwright Operator Good afternoon.

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2023 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.93 per share a year ago.

Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results.

Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals announces it will report its second quarter 2023 financial results on Thursday, August 10, 2023.

Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023

Annovis Bio

Novo Nordisk

Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.

3 Biotech Stocks to Buy Before Drug Trials End

Amylyx focuses on neurodegenerative diseases. After launching its first product in September, the company turned its first profitable quarter.

Why Shares of Amylyx Pharmaceuticals Were Up Monday

Alkami Technology

Carnival

Some of the notable companies to have witnessed solid earnings acceleration as of now are Carnival (CCL), Amylyx Pharmaceuticals (AMLX) and Alkami Technology (ALKT).

3 Stocks Worth a Buy for Remarkable Earnings Acceleration

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Webcast to Discuss the PSP Treatment Landscape and the Company's Clinical Development Plans on July 26, at 1:30pm ET.

Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program

Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclerosis.

Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 - Will Seek Re-Examination.

Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx signs LOI with the pCPA for ALBRIOZA™ and will now work with drug plans to ensure public coverage to eligible Canadians with ALS.

Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS

Viking Therapeutics

Amylyx Pharmaceuticals and Viking Therapeutics have been on fire over the past year. Even so, both companies still look incredibly undervalued relative to their long-term growth potential.

Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.

Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Shares have lost a third of their value year to date. Relyvrio launch in ALS has produced promising metrics out of the gate and the company will be generating positive cash flow going forward. The confirmatory readout from PHOENIX trial in 2024 is a key concern, as in the worst-case scenario Relyvrio could be pulled off the market if no benefit is observed.

Amylyx Pharmaceuticals: Post Q1 Selloff Appears Overdone

Amylyx Pharmaceuticals Inc said on Tuesday the European drug regulator was likely to reject its amyotrophic lateral sclerosis (ALS) drug, sending its shares down 8.5% in premarket trading.

Amylyx says European drug regulator likely to reject ALS drug

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union.

Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union

The biotech sector is notoriously volatile, populated with plenty of unprofitable companies that soar on optimism about clinical trials. Those same stocks can later plummet on poor trial results, or a delay when it comes to regulatory approval.

Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch

Amylyx Pharmaceuticals, a biotech firm focusing on neurodegenerative disorders, has seen impressive Q1 2023 financial performance despite clinical uncertainties around its flagship product, Relyvrio. Relyvrio, an ALS treatment drug, generated $71.4 million in revenue, bolstering predictions of annual revenues surpassing $1 billion.

Amylyx: A Biotech Underdog's Resilient Performance And Promising Market Potential

Sarepta Therapeutics

Growth stocks have been top-performers during the first five months of 2023. This broad-based rally is in danger of stalling because of numerous storm clouds on the horizon.

2 Supercharged Growth Stocks to Buy Right Now

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer and Co-Founder Margaret Olinger - Global Head of Commercial and CCO James Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer and Co-Founder Conference Call Participants Corinne Jenkins - Goldman Sachs Marc Goodman - SVB Securities Ananda Ghosh - H.C. Wainwright Neena Bitritto-Garg - Citi Lindsey Allen Good afternoon and thank you for joining today to discuss our First Quarter 2023 Earnings.

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2023 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to loss of $0.93 per share a year ago.

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 Earnings and Revenues Surpass Estimates

Amylyx Pharmaceuticals reported an unexpected first-quarter gain and sales blew past forecasts. In response, AMLX stock rocketed.

News for Amylyx Pharmaceuticals Stock (AMLX)